CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

NCT07234110 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed and Refractory CD5 Hematological Tumors

Interventions

DRUG: Fully human CD5 chimeric antigen receptor T cell injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]